Relay Therapeutics Hits Day Low of $12.93 Amid Price Pressure

Relay Therapeutics, Inc. experienced a notable decline in its stock performance today, with a decrease of 7.02% as of June 5, 2026. The stock reached an intraday low of USD 12.93, reflecting a challenging trading session for the small-cap pharmaceutical and biotechnology company. In terms of performance metrics, Relay Therapeutics has shown a mixed trend over various time frames. While the stock has surged by 317.28% over the past year, significantly outperforming the S&P 500's 24.32% return, it has faced a decline of 3.77% over the past week. Year-to-date, the stock remains up by 59.81%, again surpassing the S&P 500's 7.86% gain. Despite the recent downturn, the company has reported positive results in its last two consecutive quarters, with net sales for the first half of the year reaching USD 10 million. However, it is important to note that the stock is trading at a higher risk compared to its historical valuations, and its operating cash flow remains negative at USD -213.35 million. The high institutional ownership at 100% indicates strong backing from investors with substantial analytical resources.